Review on "Ozempic Face" and Facial Aging With GLP-1 Receptor Agonists
This review describes facial changes called "Ozempic face" linked to rapid weight loss with GLP-1 receptor agonists and proposes a framework for assessment and counseling. [1]
Automatic summary · not editorially reviewed
The key findings
The review addresses facial changes associated with rapid weight loss, described by the popular term "Ozempic face" as accelerated facial aging in patients on these medications. [1]
The review examines anatomical and histological bases, including dermal white adipose tissue, skeletal remodeling and sarcopenia, and outlines a practical framework for assessment and counseling. [1]
As GLP-1 receptor agonists expand into new indications including inflammatory skin diseases, dermatology clinicians are positioned to counsel and manage affected patients. [1]
The source at a glance
- Study type / format
- Review (abstract)
- Population / context
- Patients on GLP-1 receptor agonists with weight-loss-associated facial changes
- Summary based on
- Study abstract
- Original publication
- October 10, 2026
Facial changes linked to rapid weight loss
The review addresses a clinical challenge for dermatologists and cosmetic practitioners: facial changes associated with rapid weight loss. The popular term "Ozempic face" describes the appearance of accelerated facial aging in patients on these medications. The authors characterize it by volume deflation, skin laxity and loss of structural support.
Supporting source [1]
Tissue roles and a proposed assessment framework
The review examines the anatomical and histological basis of these changes, with attention to dermal white adipose tissue, skeletal remodeling and sarcopenia. It discusses the clinical presentation of weight-loss-associated facial change and outlines a practical framework for patient assessment and counseling. The timing and sequencing of interventions across the weight loss journey are addressed, with emphasis on a health-first approach that prioritizes tissue preservation.
Supporting source [1]
Dermatology role as GLP-1 indications expand
As GLP-1 receptor agonists expand into new therapeutic indications, including inflammatory skin diseases, dermatology clinicians are uniquely positioned to counsel and manage patients experiencing these changes. The abstract does not report study design, sample size, follow-up or outcome data. The full text was not reviewed.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. The abstract reports no study design, sample size, follow-up or outcome data, and the proposed framework is not described as validated.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Fathizadeh S, Hwang AS, Hoss E. · europepmc.org · October 10, 2026